A Randomized, Double-Blind, Placebo-Controlled Study of
Dronabinol in the Treatment of Marijuana Dependence
Please refer to this study by identifier 4886
Principal Investigator(s) Frances Levin
Purpose
We propose a 12 week, double-blind, placebo-controlled treatment trial testing the agonist dronabinol in conjunction with a psychosocial intervention targeting symptoms of irritability. We hypothesize that reducing withdrawal symptoms will result in greater retention in treatment and lead to higher rates of abstinence in treatment-seeking marijuana users.
Type of Study: Clinical Trial Setting of Study: outpatient Clinical Trials.gov number: NCT00217971 Providing Clinical Treatment?: Yes No Cost Treatment?: Yes Care is provided in languages: English
Study Activities
Filling Out Forms Computer Tasks Blood Samples Psychophysiology measurements Provides Payment: Reimbursement for transportation Provides Payment: Compensation for study related procedures
Eligibility
Ages Eligible for Study: 18 Years - 65 Years Genders Eligible for Study: Both
This study is not recruiting Healthy Volunteers.
Criteria
Location: 513 west 166th street
3rd floor
new york, ny 10032 Clinic: Substance Treatment and Research Services Division: Substance Abuse
Study chairs or principal investigators: Frances Rudnick Levin M.D., Principal Investigator
